• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TRICIRIBINE Drug Record

  • Summary
  • Interactions
  • Claims
  • TRICIRIBINE chembl:CHEMBL331237 Antineoplastic

    Alternate Names:

    NSC-154020

    Drug Info:

    FDA Approval not approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    (3 More Sources)

    Publications:

    Arqués et al., 2016, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer., Clin. Cancer Res.
    Garrett et al., 2011, Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT., Invest New Drugs
  • TRICIRIBINE   CTNNB1

    Interaction Score: 1.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy NVP-TNKS656 + Triciribine
    Indication/Tumor Type colon cancer
    Response Type predicted – sensitive

    PMIDs:
    26224873


    Sources:
    JAX-CKB

  • TRICIRIBINE   AKT3

    Interaction Score: 1.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name triciribine-phosphate, TCN-P, VQD-002
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial

  • TRICIRIBINE   AKT2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name triciribine-phosphate, TCN-P, VQD-002
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial

  • TRICIRIBINE   AKT1

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type no benefit

    PMIDs:
    20644979


    Sources:
    ClearityFoundationBiomarkers TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB

  • TRICIRIBINE   NFE2L2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TdgClinicalTrial: TRICIRIBINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval not approved

    Publications:

  • JAX-CKB: Triciribine

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Arqués et al., 2016, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer., Clin. Cancer Res.
    Garrett et al., 2011, Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT., Invest New Drugs

  • TTD: TRICIRIBINE

    • Version: 2020.06.01

    Alternate Names:
    D04GSV TTD Drug ID

    Drug Info:

    Publications:

  • DTC: TRICIRIBINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL331237 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL331237

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: TRICIRIBINE

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: TRICIRIBINE

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21